Joseph Kim, MD, on Liquid Biopsies as a Diagnostic for GI Cancers

Article

The chief of surgical oncology at the UK Markey Cancer Center discussed liquid biopsies and their potential importance for diagnosing gastric cancer.

Joseph Kim, MD, chief of the division of surgical oncology at the UK Markey Cancer Center, spoke about the importance of liquid biopsies, specifically in gastric cancer, at the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. 

 

Transcription:

Currently, liquid biopsies are really in their infancy in diagnostics for (gastrointestinal) cancers, especially gastric cancer. Liquid biopsies are being tested in a number of cancers, but I think it’s particularly important for gastric cancer where it may be difficult to get enough tissue to do all of the genetic testing that we need, and so the liquid biopsies provide an avenue for us to get that data which would potentially help change the type of treatments that are offered for patients with gastric cancer. 

Recent Videos
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
Related Content